Immunotherapy in Prostate Cancer

被引：1
|
作者：
Bolat, Deniz [1 ,3 ]
Haydaroyu, Ayfer [2 ,3 ]
机构：
[1] Univ Hlth Sci, Izmir Bozyaka Training & Res Hosp, Clin Urol, Izmir, Turkey
[2] Ege Univ, Dept Radiat Oncol, Fac Med, Izmir, Turkey
[3] Ege Univ, Inst Hlth Sci, Dept Basic Oncol, Izmir, Turkey
来源：
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2019年 / 18卷 / 02期
关键词：
Prostate cancer; immunotherapy; vaccine; checkpoint blockers; survival; PHASE-III TRIAL; SIPULEUCEL-T; ANDROGEN DEPRIVATION; CTLA-4; BLOCKADE; DOSE-ESCALATION; PD-1; DOUBLE-BLIND; SURVIVAL; VACCINE; CHEMOTHERAPY;
D O I：
10.4274/uob.galenos.2018.1142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (FDA) approval of sipuleucel-T for asymptomatic or minimal symptomatic metastatic castration-resistant prostate cancer (CRPC). Despite all these developments, the patients in whom these agents should be used, sequential use and combination strategies remain unclear. In this review, mechanisms of action and survival outcomes of different immunotherapeutic agents and therapeutic cancer vaccines in mCRPC are discussed.
引用
下载
收藏
页码：67 / 72
页数：6
相关论文
共 50 条
  • [21] The immunotherapy of prostate cancer
    AG Dalgleish
    MJA Perry
    JD Eaton
    D Hrouda
    SM Todryk
    RS Kirby
    Prostate Cancer and Prostatic Diseases, 2000, 3 : 303 - 307
  • [22] The immunotherapy of prostate cancer
    Dalgleish, AG
    PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE, 2003, : 191 - 194
  • [23] Promising immunotherapy for prostate cancer
    Henegan, John C.
    Sonpavde, Guru
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (02) : 109 - 120
  • [24] Advances in immunotherapy for prostate cancer
    Markiewicz, MA
    Kast, WM
    ADVANCES IN CANCER RESEARCH, VOL 87, 2003, 87 : 159 - 194
  • [25] Immunotherapy for the treatment of prostate cancer
    Giuseppe Di Lorenzo
    Carlo Buonerba
    Philip W. Kantoff
    Nature Reviews Clinical Oncology, 2011, 8 : 551 - 561
  • [26] Breakthrough in the immunotherapy of prostate cancer?
    Miller, K
    AKTUELLE UROLOGIE, 2005, 36 (05)
  • [27] Immunotherapy approved for prostate cancer
    不详
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1763 - 1763
  • [28] Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo, Alessandro
    Mollica, Veronica
    Cimadamore, Alessia
    Santoni, Matteo
    Scarpelli, Marina
    Giunchi, Francesca
    Cheng, Liang
    Lopez-Beltran, Antonio
    Fiorentino, Michelangelo
    Montironi, Rodolfo
    Massari, Francesco
    CELLS, 2020, 9 (09) : 1 - 24
  • [29] Prostate cancer - Advances in immunotherapy
    Hurwitz, AA
    Yanover, P
    Markowitz, M
    Allison, JP
    Kwon, ED
    BIODRUGS, 2003, 17 (02) : 131 - 138
  • [30] IMMUNOTHERAPY OF PROSTATE-CANCER
    SCHULZE, H
    SOMMERFELD, HJ
    UROLOGE-AUSGABE A, 1993, 32 (05): : 382 - 389
12345